Alpha Tau Medical presented clinical results of its alpha radiation cancer treatment at ASTRO

Alpha Tau Medical Ltd., (Israel) presented preliminary clinical results of its alpha-radiation-based brachytherapy (Alpha DaRT) at ASTRO (American Society for Therapeutic Radiation Oncology) on October 23 in San Antonio, Texas, USA. HekaBio has partnered with Alpha Tau Medical to develop and commercialize the Alpha DaRT cancer treatment for solid tumors in Japan.

The clinical results carried out in Israel were from 15 subjects who completed follow-up for 30-45 days, resulting in an overall response rate of 100% and a complete response rate over 73%. Some of the subjects were elderly patients who were medically unfit for surgery or failed previous external beam radiation. It was demonstrated that the Alpha DaRT can be administered safely under local anesthesia in an outpatient setting for all of the patients, including the given sensitive cases.

Please refer to the attached poster for the content of the clinical trial.


About Alpha Tau Medical LTD

Alpha Tau Medical is an Israeli medical device company that focuses on research, development and commercialization of Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) for the treatment of solid tumor cancers. The Alpha DaRT technology was developed by Prof. Itzhak Kelson and Prof. Yona Keisari in 2003 at Tel Aviv University. The company strives “to enable a cancer treatment that destroys tumors while sparing healthy tissue to save the lives of millions of patients around the world.” (Alpha Tau Medical, Mission Statement)

For more information, please visit http://www.alphatau.com/



About Alpha DaRT

The Alpha DaRT has several important advantages:

• Highly potent and conformal

• Proven efficacy for all solid tumors tested

• Stimulates anti-tumor immune response

• Low toxicity, no known negative systemic effects

• Effective regardless of tumor oxygen level

• Short half-life – quick clinical outcome

• Single-session treatment

• Enables combination with other therapies or reapplication

• Disposable applicators - does not require capital equipment or special shielding




最新記事

すべて表示

AlphaTau Medical LtdとHealthcare Capital Corp.が合併し、アルファ粒子線照射による固形腫瘍の治療に焦点を当てた10億ドル規模の上場企業を設立

ヘカバイオ株式会社のパートナー企業であるAlpha Tau Medical Ltd は7月9日(現地時間7月8日)に、Special Purpose Acquisition Company(特別買収目的会社)であるHealthcare Capital Corp.(Nasdaq:HCCC)と共に上場企業を設立し、2021年末にかけてNasdaqへ上場すると発表しました。 両社によるプレスリリースはこ

ポリープ状脈絡膜血管症(加齢黄斑変性症の一種)の先進的治療を開発するSalutarisMD社とライセンス契約を締結

ヘカバイオ株式会社(以下、ヘカバイオ)は、加齢黄斑変性症の中でもアジア人に多いポリープ状脈絡膜血管症(PCV)の治療のため開発されたBetaCurveの日本におけるライセンスおよび商業化の契約をSalutaris Medical Devices Inc.(以下SalutarisMD社)と締結しました。 同社が開発したBetaCurveは、Sr90(ストロンチウム90:放射性同位元素)を用いたβ線を

新株発行により4億円の資金調達を達成

ヘカバイオ株式会社(東京都中央区日本橋本石町3-3-16)は2021年1月29日付にて4億円の第三者割当増資を行いました。 今回の増資により調達した資金は、今後当社が開発を手掛けるポートフォリオを拡充させるために活用いたします。 当社は、人々の医療と健康への貢献を使命として、世界への窓口として日本にベースに置き、海外の製品の導入に特化して開発や市場化を行っています。がん、線維性疾患、自己免疫性炎症